The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients. The estimated incidence of PM/DM is approximately 5 to 22 cases per 100,000 individuals.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

MARCH 8, 2025

The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% “PN is an intensely itchy skin disease, and for many years, there were no approved therapies, he says. The overall safety profile of ruxolitinib cream 1.5%

Safety 36

Safety Clinic Therapy Dermatology 36

The Dermatology Digest

MARCH 17, 2025

The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and 30-day safety follow-up. 75mg: 40.6% 75mg: 42.3%

Safety 36

Safety Document Clinic Therapy 36

Aesthetics Exposed

MARCH 22, 2019

Lasers and light therapies are among the most commonly used devices in the esthetic industry. Modern day usage of light has broadly expanded the range of cosmetic medical treatments. There are three main types of light therapy used in esthetics: LED, IPL and lasers. What is Light? Light behaves as both a particle and a wave.

Hair Removal 195

Hair Removal Esthetics Collagen Rosacea 195

Alison Bladh

JANUARY 1, 2025

Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Dermatologic Therapy. Platelet-Rich Plasma Therapy for Hair Growth: A Systematic Review. Microblading: Safety and Efficacy in Eyebrow Enhancement.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. At week 24, 42.3% difference vs. placebo. At week 24, 22.7% difference vs. placebo.

Dermatitis 36

Dermatitis Safety Office Eczema 36

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. Ch’en, a medical student at the Albert Einstein College of Medicine in the Bronx, New York, and Peter A.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

NOVEMBER 6, 2024

” The TBA recipients include: Innovating Pain and Fatigue Management Cynthia Aranow, MD, The Feinstein Institutes for Medical Research Dr. Aranow will evaluate the use of a new, non-toxic, non-painful device that stimulates the vagus nerve to reduce pain and fatigue in people with SLE.

Hospital 36

Hospital Therapy Networking Management 36

US Dermatologt Partners

JUNE 1, 2024

In the ever-evolving landscape of psoriasis treatment, oral therapies continue to play a crucial role. These medications have been staples in psoriasis management, particularly in countries like Germany, where they are frequently prescribed for moderate to severe cases. and a PASI 90 response rate of 22.3%.

Therapy 41

Therapy Injections Safety Management 41

The Dermatology Digest

AUGUST 20, 2024

Food and Drug Administration (FDA) approved apremilast for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. The adverse events were consistent with the known safety profile of Otezla in adult patients.

Safety 74

Safety Injections Therapy Treatments 74

The Dermatology Digest

MARCH 9, 2025

The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period.

Sustainability 36

Sustainability Hospital Clinic Dermatology 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Dr. Krystal Briglia, L+A Medical + Wellness Editor Dr. Krystal Briglia of Triada Integrative Medicine + Wellness is a board-certified nurse practitioner specializing in aesthetic dermatology, integrative medicine, and wellness. Dermatologic Therapy. Journal of Dermatologic Therapy Wu, D., Farris, P. Goldberg, D. Rigopoulos, D.,

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

The Dermatology Digest

MARCH 18, 2025

has completed enrollment in its Phase 3 clinical trial evaluating aminolevulinic acid hydrochloride (Ameluz) with photodynamic therapy (PDT) for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk. Biofrontera Inc.

Treatments 36

Treatments Dermatology Safety Therapy 36

The Dermatology Digest

FEBRUARY 8, 2024

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

JULY 24, 2024

We will prioritize quality, broaden choices for medical professionals, and provide superior experiences and accessibility to the consumers.” . “We are confident that Hugel’s established track record in South Korea, coupled with BENEV’s network, will resonate well with the U.S.

Dermatology 78

Dermatology Sales Marketing Safety 78

The Dermatology Digest

FEBRUARY 10, 2025

Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate proliferation of inhibitory immune cells known as regulatory T cells. “We are pleased that rezpegaldesleukin has been designated a Fast Track product,” says Jonathan Zalevsky, Ph.D.,

Dermatitis 36

Dermatitis Therapy Office Safety 36

New Age Spa Institute

NOVEMBER 20, 2024

Licenses like those for esthetics, cosmetology , and massage therapy give professionals the legal right to practice their craft and offer services to the public. Choosing Between Esthetics, Cosmetology & Massage Therapy One of the most common questions we hear is, “ What’s the difference between an esthetician and a cosmetologist?

Esthetics 52

Esthetics Therapy Continuing Education Continuous Education 52

US Dermatologt Partners

MARCH 27, 2024

Red light therapy is considered one of the newest and most innovative skin rejuvenation procedures available. Dermatology Partners in Cedar Park, Texas , “ Red light therapy is so new that the dermatologic community hasn’t even settled on one name for it. What is Red Light Therapy? According to Dr. Jean Charles of U.S.

Therapy 41

Therapy Treatments Dermatology Collagen 41

US Dermatologt Partners

JANUARY 13, 2025

Desai, During professional acne extractions, I carefully cleanse skin, prep the area with numbing medications, and remove acne lesions without causing unnecessary trauma to the surrounding tissue. They also use topical and/or injected numbing medications to make the procedure more comfortable.

Extractions 41

Extractions Scarring Pores Chemical Peels 41

The Dermatology Digest

FEBRUARY 11, 2024

This particular study did not address other safety concerns, such as all-cause mortality, infections, or cancer. Nonetheless, in this large cohort, treated for a median duration of 16 weeks, there was no detectable cardiovascular risk in those receiving oral JAK inhibitor therapy. Ireland PA, Jansson N, Spencer SKR.

Dermatology 74

Dermatology Safety Clinic Therapy 74

American Esthetician Organization

AUGUST 17, 2023

From topical creams to oral medications, finding the right solution for this chronic skin condition can feel like an endless battle. However, there’s a new contender in the field of rosacea treatments that’s gaining momentum – laser therapy. These treatments typically involve topical medications or oral antibiotics.

Rosacea 88

Rosacea Treatments Medical Management 88

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

The Dermatology Digest

OCTOBER 30, 2024

Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Shiri Nawrocki received $10,000 for her study titled, “Development of Patient-centered education materials for Dermatologic Toxicities of Anticancer Therapies in a Diverse Patient Population.”

Sun Protection 36

Sun Protection Dermatology Safety Innovations 36

Aesthetics Advisor

AUGUST 15, 2023

Disclaimer: We in no way endorse the Joe Tippens Cancer Protocol as a cure for cancer, and as always, you should consult your physician before starting any new medications or treatment plans. Curcumin may help increase healthy p53 levels, and it has been shown to be a potentially effective cancer therapy supplement.

Therapy 69

Therapy Medical Safety Diet 69

The Dermatology Digest

SEPTEMBER 20, 2024

Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s s Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). Dr. Robert B.

Office 74

Office Clinic Safety Medical 74

Aesthetics Advisor

AUGUST 18, 2023

Key Points: A few studies show that NAD+ IV therapy can alleviate alcohol and drug addiction, as well as Parkinson’s disease, but no studies have examined its effects on aging. Oral administration of NAD+ boosting therapy is safer, more cost effective, and more consistently dosed than intravenous administartion.

Therapy 36

Therapy Injections Safety Clinic 36

The Dermatology Digest

JANUARY 21, 2024

What’s more, delgocitinib cream 20 mg/g was well-tolerated over 16 weeks, and no safety concerns were identified. Oral medications like alitretinoin are not available in all areas and not approved for use in the U.S so access to medications can be limiting. Study author Melinda J. The bottom line? Enter JAK inhibition.

Safety 36

Safety Eczema Social Media Dermatology 36

AAFE - American Academy of Facial Esthetics

APRIL 22, 2024

Unveiling the Differences: PRF vs. PRP Platelet-Rich Plasma (PRP): PRP therapy involves extracting a patient’s blood, processing it to isolate platelets, and then re-injecting the concentrated platelets into targeted areas of the face.

Injections 60

Injections Facials Collagen Therapy 60

Aesthetics Advisor

JULY 4, 2024

In recent years, the allure of IV drip therapy has surged, captivating both health enthusiasts and celebrities alike. This intriguing medical innovation promises a plethora of health benefits, leaving many curious minds wondering: What magic lies within those IV bags, and is it truly transformative? What is IV drip therapy?

Therapy 36

Therapy Vitamin C Injections Medical 36

The Dermatology Digest

FEBRUARY 14, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

MARCH 12, 2024

in patients with HS met its primary endpoint, reinforcing the efficacy and safety profile of ruxolitinib cream 1.5%, demonstrating potential as a novel treatment option for people living with HS,” study author Martina J. Porter, MD, a dermatologist at Beth Israel Deaconess Medical Center in Boston, tells TDD.

Therapy 69

Therapy Dermatology Safety Treatments 69

Aesthetics Advisor

AUGUST 19, 2023

Nevertheless, PRP and exosome-related therapies are not yet established as standard treatments, given their relatively recent emergence. Regenerative medicine is also becoming a buzzword in the medical community. Because the human body is specially equipped to heal itself, and regenerative therapies tap into this powerful ability.

Therapy 36

Therapy Injections Treatments Medical 36

AAAMS

AUGUST 4, 2023

It reduces disability, diminishes reliance on pain medications and heightens daily functioning, enabling patients to reclaim their lives from the grip of migraines. While some patients may be free of migraines through Botox alone, others may need additional treatments or therapies. Why Use Botox as a Treatment for Migraines?

Injections 52

Injections Surgery Medical Training 52

The Dermatology Digest

MAY 8, 2024

The safety profile of subcutaneous nivolumab was consistent with the IV formulation. The pharmacokinetics, efficacy, and safety results from CheckMate -67T were presented at the American Society of Clinical Oncology (ASCO) 2024 Genitourinary Cancers Symposium. “An

Safety 36

Safety Therapy Injections Dermatology 36

AAAMS

AUGUST 4, 2023

It reduces disability, diminishes reliance on pain medications and heightens daily functioning, enabling patients to reclaim their lives from the grip of migraines. While some patients may be free of migraines through Botox alone, others may need additional treatments or therapies. Why Use Botox as a Treatment for Migraines?

Injections 52

Injections Surgery Medical Training 52

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Topical or systemic AD medications were not permitted during the study. and Canada. with IGA=4.

Safety 36

Safety Therapy Dermatitis Dermatology 36